TRAIL, also known as APO2-L or TNF-Related Apoptosis-Inducing Ligand and its derivatives, including agonistic antibodies targeting TRAIL receptors or PARAs (ProApoptotic Receptor Agonists), are attractive compounds for cancer therapy due to their ability to induce tumor regression without significant side effects [1]. This evidence concerns the gene TNFSF10 and cancer.